24/07/2026 Sanofi announced its decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews Sanofi announced its decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews (Ref) Sanofi announced the discontinuation of clinical development of amlitelimab (OX40-ligand) in moderate-to-severe atopic dermatitis (AD). The decision followed a strategic pipeline review, that concluded the overall efficacy and safety data did not su